Shots:

• Janssen reported pooled analyses of long-term follow-up from multiple clinical trials evaluating the use of Imbruvica monothx. and in combination as a 1L treatment for patients with CLL with high-risk features
• Results from an integrated analysis of two clinical trials with ~79mos. of follow-up demonstrated PFS rates (63%-82%) @42mos.; median duration of treatment across high-risk subgroups (35.7-43.8 mos.)
• Additionally- data with a median follow-up of >4yrs. were presented from a pooled analysis of 89 patients with high-risk CLL bearing TP53 aberrations from 4 trials. Further- data from the RWE studies highlight the benefit of ibrutinib-based therapies in a 1L setting

 ­ Ref: Businesswire | Image: Janssen